• 1
    World Health Organization. Fact Sheet No. 297, 2006.
  • 2
    Papanicolaou GN. Science. 1942; 95: 438439.
  • 3
    Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993; 12: 186192.
  • 4
    Grace A,McBrearty P,Troost S,Thornhill M,Kay E,Leader M. Comparative study: conventional cervical and ThinPrep Pap tests in a routine clinical setting. Cytopathol. 2002; 13: 200205.
  • 5
    Weintraub J,Morabia A. Efficacy of a liquid-based thin layer method for cervical cancer screening in a population with a low incidence of cervical cancer. Diagn Cytopathol. 2000; 22: 5259.
  • 6
    Dziura B,Quinn S,Richard K. Performance of an imaging system vs. manual screening in the detection of squamous intraepithelial lesions of the uterine cervix. Acta Cytol. 2006; 50: 309311.
  • 7
    Biscotti CV,Dawson AE,Dziura B, et al. Assisted primary screening using the automated ThinPrep Imaging System. Am J Clin Pathol. 2005; 123: 281287.
  • 8
    RiesLAG,EisnerMP,KosaryCL,HankeyBF,MillerBA,CleggL,MariottoA,FayMP,FeuerEJ,EdwardsBK (eds.) SEER Cancer Statistics Review, 1975–2000. National Cancer Institute, Bethesda, MD, 2003.
  • 9
    Stoler MH,Schiffmann M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001; 285: 15001505.
  • 10
    Walboomers JM,Jacobs MV,Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 1219.
  • 11
    Ho GY,Bierman R,Beardsley L,Chang CJ,Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Eng J Med. 1998; 338: 423428.
  • 12
    The ASCUS-LSIL Triage Study Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol. 2003; 188: 13931400.
  • 13
    The ASCUS-LSIL Triage Study Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003; 188: 13831392.
  • 14
    Galloway DA,McDougall JK. The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia. Semin Cancer Biol. 1996; 7: 309315.
  • 15
    Khleif SN,DeGregori J,Yee CL, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci U S A. 1996; 93: 43504354.
  • 16
    Chellappal S,Kraus VB,Kroger B, et al. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Nat Acad Sci U S A. 1992; 89: 45494553.
  • 17
    Serrano M,Hannon GJ,Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993; 366: 704707.
  • 18
    Li Y,Nichols MA,Shay JW,Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res. 1994: 54: 60786082.
  • 19
    Klaes R,Friedrich T,Spitkovsky D, et al. Overexpression of p16(INK4a) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001; 92: 276284.
  • 20
    Sano T,Oyama T,Kashiwabara K,Fukuda T,Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol. 1998; 153: 17411748.
  • 21
    Keating JT,Cviko A,Riethdorf S, et al. Ki-67, cyclin E, and p16INK4a are complementary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol. 2001; 25: 884891.
  • 22
    Agoff N,Lin P,Morihara J,Mao C,Kiviat N,Koutsky L. p16INK4a expression correlates with degree of cervical neoplasia: A comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol. 2003; 16: 665673.
  • 23
    Stanley MA. Prognostic factors and new therapeutic approaches to cervical cancer. Virus Res. 2002; 89: 241248.
  • 24
    Saqi A,Pasha T,McGrath CM,Yu GH,Gupta P. Overexpression of p16INK4a in liquid-based specimens (SurePath) as marker of cervical dysplasia and neoplasia. Diagn Cytopathol. 2002; 27: 365370.
  • 25
    Jones BA,Novis D. Cervical biopsy–cytology correlation. A College of American Pathologists Q-Probes study of 22 439 correlations in 348 laboratories. Arch Pathol Lab Med. 1996; 120: 523553.
  • 26
    Nieh S,Chen SF,Chu TY, et al. Is p16(INK4A) expression more useful than human papillomavirus test to determine the outcome of atypical squamous cells of undetermined significance-categorized Pap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies. Gynecol Oncol. 2005; 97: 3540.
  • 27
    Bose S,Evans H,Lantzy L,Scharre K,Youssef E. p16(INK4A) is a surrogate biomarker for a subset of human papilloma virus-associated dysplasias of the uterine cervix as determined on the Pap smear. Diagn Cytopathol. 2005; 32: 2124.
  • 28
    Nieh S,Chen SF,Chu TY,Lai HC,Fu E. Expression of p16INK4A in Pap smears containing atypical glandular cells from the uterine cervix. Acta Cytol. 2004; 48: 173180.
  • 29
    Guo M,Hu L,Baliga M,He Z,Hughson MD. The predictive value of p16INK4a and hybrid capture 2 human papillomavirus testing for high-grade cervical intraepithelial neoplasia. Am J Clin Pathol. 2004; 122: 894901.
  • 30
    Nieh S,Chen SF,Chu TY,Lai HC,Fu E. Expression of p16 INK4A in Papanicolaou smears containing atypical squamous cells of undetermined significance from the uterine cervix. Gynecol Oncol. 2003; 91: 201208.
  • 31
    Pientong C,Ekalaksananan T,Swadpanich U, et al. Immunocytochemical detection of p16INK4a protein in scraped cervical cells. Acta Cytol. 2003; 47: 616623.